Related Experiment Video
Updated: Sep 2, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Transforming Growth Factor β3 (TGF-β3) Signaling: A Potential Target for Cancer Therapy
Zan-Wen Zuo1, Wen-Jing Tang1, Qian Zhang1
1Innovative Drug R&D Center, Anhui Provincial Engineering Laboratory for Efficient Utilization of Featured Resource Plants, Huaibei Key Laboratory of Efficient Cultivation and Utilization of Resource Plants, College of Life Sciences, Huaibei Normal University. Huaibei 235000, PR China.
Abstract:
Transforming growth factor β (TGF-β) signaling is essential for early embryonic development, tissue and organ formation, immune surveillance, tissue repair, and maintaining homeostasis in adults. The three isoforms of TGF-β, TGF-β1/2/3, share a structurally conserved secretion signal peptide and activate various downstream signaling pathways. While much research has focused on TGF-β1, there is increasing recognition of the important roles that TGF-β3 plays in cancer biology. TGF-β3 exhibits dual functions. It can inhibit tumors in the early stages of cancer but can promote tumor growth in more advanced stages. Understanding the unique characteristics of TGF-β3 is crucial for unraveling the complexities of tumor development and the tumor microenvironments. Targeting TGF-β signaling is considered a promising strategy for cancer treatment, and developing drugs aimed at TGF-β3 holds significant potential. In the future, TGF-β3 targeted therapies are expected to gain more attention as a means to enhance therapeutic outcomes and address poor prognoses in cancer patients.
Related Concept Videos
TGF - β Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
The Tumor Microenvironment
Regulation of Angiogenesis and Blood Supply

